These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33341445)

  • 41. Near complete resolution of refractory, relapsed, metastatic Wilms' tumour in an adolescent with bevacizumab.
    Kumar S; Burney IA; Al-Moundhri MS
    J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S71-2. PubMed ID: 24718015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the clinical management of high-risk Wilms tumors.
    Ortiz MV; Koenig C; Armstrong AE; Brok J; de Camargo B; Mavinkurve-Groothuis AMC; Herrera TBV; Venkatramani R; Woods AD; Dome JS; Spreafico F
    Pediatr Blood Cancer; 2023 May; 70 Suppl 2(Suppl 2):e30342. PubMed ID: 37096797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The evolution of treatment for Wilms tumor.
    Green DM
    J Pediatr Surg; 2013 Jan; 48(1):14-9. PubMed ID: 23331787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
    Irtan S; Jitlal M; Bate J; Powis M; Vujanic G; Kelsey A; Walker J; Mitchell C; Machin D; Pritchard-Jones K;
    Eur J Cancer; 2015 Jan; 51(2):225-32. PubMed ID: 25465191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.
    Dome JS; Graf N; Geller JI; Fernandez CV; Mullen EA; Spreafico F; Van den Heuvel-Eibrink M; Pritchard-Jones K
    J Clin Oncol; 2015 Sep; 33(27):2999-3007. PubMed ID: 26304882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour.
    Maschietto M; Piccoli FS; Costa CM; Camargo LP; Neves JI; Grundy PE; Brentani H; Soares FA; Camargo Bd; Carraro DM
    Eur J Cancer; 2011 Dec; 47(18):2715-22. PubMed ID: 21703850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anaplasia in Wilms tumor: A critical review.
    Vujanić GM; Mifsud W
    Pediatr Blood Cancer; 2024 Jul; 71(7):e31000. PubMed ID: 38605554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Similarities and controversies in imaging of pediatric renal tumors: A SIOP-RTSG and COG collaboration.
    van der Beek JN; Artunduaga M; Schenk JP; Eklund MJ; Smith EA; Lederman HM; Warwick AB; Littooij AS; Khanna G
    Pediatr Blood Cancer; 2023 May; 70 Suppl 2():e30080. PubMed ID: 36349564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The advantages of preoperative therapy in Wilms' tumour. A summarised report on clinical trials conducted by the International Society of Paediatric Oncology (SIOP).
    Bürger D; Moorman-Voestermans CG; Mildenberger H; Lemerle J; Voûte PA; Tournade MF; Rodary C; Delemarre JF; Sandstedt B; Sarrazin D
    Z Kinderchir; 1985 Jun; 40(3):170-5. PubMed ID: 2994320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
    Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
    Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in the clinical management of high-risk Wilms tumors.
    Ortiz MV; Koenig C; Armstrong AE; Brok J; de Camargo B; Mavinkurve-Groothuis AMC; Herrera TBV; Venkatramani R; Woods AD; Dome JS; Spreafico F
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30153. PubMed ID: 36625399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single centre experience over 11 years.
    Bergeron C; Iliescu C; Thiesse P; Bouvier R; Dijoud F; Ranchere-Vince D; Basset T; Chappuis JP; Buclon M; Frappaz D; Brunat-Mentigny M; Philip T
    Eur J Cancer; 2001 Feb; 37(3):385-91. PubMed ID: 11239761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
    Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
    Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of promoter hypomethylation and expression of p73 as a diagnostic and prognostic biomarker in Wilms' tumour.
    Song D; Yue L; Wu G; Ma S; Yang H; Liu Q; Zhang D; Xia Z; Jia J; Wang J
    J Clin Pathol; 2016 Jan; 69(1):12-8. PubMed ID: 26184366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
    Hontecillas-Prieto L; Garcia-Dominguez DJ; Vaca DP; Garcia-Mejias R; Marcilla D; Ramirez-Villar GL; Saez C; de Álava E
    Oncotarget; 2017 Feb; 8(7):11173-11186. PubMed ID: 28061436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.
    Halliday BJ; Fukuzawa R; Markie DM; Grundy RG; Ludgate JL; Black MA; Skeen JE; Weeks RJ; Catchpoole DR; Roberts AGK; Reeve AE; Morison IM
    PLoS Genet; 2018 Jun; 14(6):e1007399. PubMed ID: 29912901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.
    Breslow NE; Ou SS; Beckwith JB; Haase GM; Kalapurakal JA; Ritchey ML; Shamberger RC; Thomas PR; D'Angio GJ; Green DM
    Cancer; 2004 Sep; 101(5):1072-80. PubMed ID: 15329918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.